This is a multicenter, randomized, double-blind, placebo-controlled trial. All patients with Panic Disorder, with or without specified co-morbidities, who meet all of the inclusion and none of the exclusion criteria will be eligible. Patients and researchers will be blinded to their treatment group.~The study will enroll approximately 80 adult patients who meet the diagnosis of panic disorder.~The patients will be treated for 12 weeks including a 1 week safety follow up visit following the last dose of study drug.
The purpose of this study is to determine the safety and efficacy of HB-1 versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with Panic Disorder.